Progression-free and overall survival is lowered in colorectal cancer patients receiving OXP treatment in those who have a loss-of-function TLR4 mutation, indicating that even with a release of HMGB1 and translocation of CRT, without an active immune system an anti-cancer vaccine environment cannot be formed [287]. The gene discussed is CALR; the disease is colorectal cancer.